entertainment -WSS

entertainment

author：explore 2025-09-14 18:26:58 - browse：5989

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Meta's Zuckerberg and Chan on track to put $50 billion into science

Wikipedia

hotspot

WSS

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

White House launches permanent pandemic office

Telehealth options flood the market as retailers push virtual care

7 of the most gruesome medical devices in history

Readout Newsletter: What happened with Sarepta's Duchenne data

A double vaccine crisis is endangering millions of children

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Trump demands the U.S. pay no more for drugs than other countries … again

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Caitlin Bernard's story shows physicians can't shy from advocacy

Malaria cases in Florida and Texas: Here’s what you need to know

Traditional Chinese medicine benefits explored in new JAMA study

How one medical school became remarkably diverse

Our daughter's deadly disease: trisomy 18. We wanted to protect her

focus

White House launches permanent pandemic office

Will.i.am, Britney Spears release new single, 'Mind Your Business'

AbbVie dramatically boosts its spending on lobbying

AbbVie dramatically boosts its spending on lobbying

New rules on organ donation and transplantation 'will bring chaos'

The FDA weighs the risks of candy

knowledge

Wikipedia

hotspot

explore